Aurigene, Agios deal

Aurigene granted Agios exclusive, worldwide rights to a portfolio of small molecule inhibitors against an undisclosed cancer metabolism target. Agios will pay Aurigene $3 million upfront and up to $17 million in development and regulatory milestones for each licensed product. Aurigene is also eligible for low single-digit royalties. Agios will conduct preclinical studies of the compound and fully fund further development and commercialization...